Analytical Data
-
基因名
Siglec-10
-
简介
Siglec-10 protein is thought to be a putative adhesion molecule that mediates sialic acid-dependent cell binding, preferentially selecting α-2,3- or α-2,6-linked sialic acid. Its sialic acid recognition site may be masked by cis interactions. Siglec-10 Protein, Human (HEK293, mFc) is the recombinant human-derived Siglec-10 protein, expressed by HEK293, with C-mFc labeled tag.
- Application
-
别名
Sialic acid-binding Ig-like lectin 10; Siglec-10; SIGLEC10; SLG2
-
种属
Human
-
表达系统
HEK293
-
标签
C-mFc
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q96LC7-1
-
表达区间
M17-T546
-
蛋白长度
Extracellular Domain
-
分子量
90-120 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Siglec-10 is a member of the Siglec (sialic acid-binding immunoglobulin-like lectin) family, which plays a crucial role in the immune system by recognizing sialic acid-containing glycoproteins and glycolipids. It is primarily expressed on immune cells, particularly in myeloid lineage, and is implicated in the regulation of immune responses, including the modulation of inflammation and the attenuation of autoimmune diseases. Research has shown that Siglec-10 can inhibit the activation of immune cells, such as macrophages and dendritic cells, thereby maintaining immune homeostasis. The significance of Siglec-10 in various pathological conditions, including cancer, has sparked interest in the development of therapeutic strategies targeting this molecule. Recombinant Siglec-10 proteins have been generated for studying its structure and function, allowing researchers to explore its potential as a biomarker for disease diagnosis and as a target for immunotherapies. Understanding the mechanisms by which Siglec-10 interacts with its ligands can provide insights into its role in health and disease, paving the way for novel treatment approaches that leverage its immune-regulatory functions. This growing body of research emphasizes the importance of characterizing Siglec-10, particularly in the context of its contributions to immune regulation, making it a promising area for future biomedical investigation.
